Sample nwwrwhu: original COA reported purity of 92.83%. Upon vendor objection, lab investigated and found the automated integration routine picked up noise as peaks and erroneously integrated it. Manual revision led to updated calculations for purity and quantity. The lab issued an updated COA. This sample's test score changed from 5.9 to 9.0, and the Finnrick Rating for Orbitrex Tirzepatide changed from B to A.
Corrections
Finnrick is committed to transparency. We rarely make changes to published test data, and when we do, we publish an explicit correction record her, and listed where relevant on individual pages of the site. Every correction includes a description of what changed and why.
Most corrections result from our vendor objections process, through which vendors can formally challenge test data they believe to be incorrect. We take every objection seriously and investigate thoroughly with the testing laboratory, and in the case of samples submitted by the public, with the submitter.
Sample p4bqre8: original COA reported purity of 97.83%. Upon vendor objection, lab investigated and found the automated integration routine picked up noise as peaks and erroneously integrated it. Manual revision led to updated calculations for purity and quantity. The lab issued an updated COA. This sample's test score changed from 3.7 to 7.0, and the Finnrick Rating for Orbitrex Retatrutide changed from D to A.
Sample potency on sample fz959qa was incorrectly captured as 0.10 mg, correct quantity was 10 mg.
Sample was incorrectly marked as having "detected" levels of endotoxins, when the amount was below the Finnrick threshold of 40 EU/sample. This has been corrected.
Two samples of Tirzepatide (4t7h769 and 9872swd) were erroneously attributed to Skye Peptides and removed from the database pending an investigation.
Submitter indicated having swapped vendor identification with sample u4q3pap. This should be OUPeptide instead of Quenna PMQ. Evidence under review, ratings might be updated.
Submitter indicated having swapped vendor identification with sample yauaeu5. This should be Quenna PMQ instead of OUPeptide. Evidence under review, ratings might be updated.
Submitter originally registered vendor as "Diju Peptides Wellness" by mistake during sample registration, the test result has been adjusted to to "LN Peptides".
Two samples of Tirzepatide were erroneously entered as from Diju Peptides Wellness, and have been moved to another vendor.
Submitter originally registered vendor as "Diju Peptides Wellness" by mistake during sample registration, the test result has been adjusted to to "LN Peptides".
This sample was entered as an Ipamorelin 5mg, Corrected to Tesamorelin 2mg
This sample was labeled as a Melanotan II 10 mg, when in fact it is a Sermorelin 5 mg. Test were entered in correct samples . Mix up was with sample xzvusxy
This sample was labeled as a Sermorelin 5mg, when in fact it is a Melanotan II 10 mg. Test were entered in correct samples . Mix up was with sample hwd8b9r
Test results published from 31 Oct to 17 Nov 2025 under Peptide Sciences, but the sample was misidentified, and re-attributed to the correct vendor.
Test results for sample 3tbve3d were published from 31 Oct to 17 Nov 2025, but did not belong to Peptide Sciences: the sample was misidentified, and re-attributed to the correct vendor.
Test results published from 31 Oct to 17 Nov 2025 under Peptide Sciences, but the sample was misidentified, and re-attributed to the correct vendor.
Test results for sample rkh8jub were published from 31 Oct to 17 Nov 2025, but did not belong to Peptide Sciences: the sample was misidentified, and re-attributed to the correct vendor.
Test results published from 31 Oct to 17 Nov 2025 under Peptide Sciences, but the sample was misidentified, and re-attributed to the correct vendor.
Test results for sample cjkyg7x were published from 31 Oct to 17 Nov 2025, but did not belong to Peptide Sciences: the sample was misidentified, and re-attributed to the correct vendor.
Test results published from 31 Oct to 17 Nov 2025 under Peptide Sciences, but the sample was misidentified, and re-attributed to the correct vendor.
Test results for sample pst3r4y were published from 31 Oct to 17 Nov 2025, but did not belong to Peptide Sciences: the sample was misidentified, and re-attributed to the correct vendor.
Test results published from 8 to 14 Nov 2025 under Peptide Sciences, but the sample was identified as a counterfeit. Results removed from publishing.
Test results for sample 87u9z6r were published from 8 to 14 Nov 2025, but did not belong to Peptide Sciences: the sample was identified as a counterfeit. They were removed from publishing.
This sample was labeled as a Tesamorelin 2mg, when in fact it is a Ipamorelin 2 mg
The sample was misslabaled by the requester, actual quantity for this sample is 50 mg, Quantity has been edited with correct value (previus value was 5 mg) and a new lab result.
The sample was misslabaled by the requester, actual quantity for this sample is 10mg, Quantity has been edited with correct value (previus value was 60 mg)
The sample was misslabaled by the requester, actual quantity for this sample is 60mg, Quantity has been edited with correct value (previus value was 10 mg)
Lab G mistakenly entered 92 mg instead of 9.2 mg.
These were remade and reanalyzed by Lab G. They traced the discrepancy to a likely human error during preparation.
These were remade and reanalyzed by Lab G. They traced the discrepancy to a likely human error during preparation.
Peptide Partners have elected to have all their samples tested against the label claim. The "batch claim" from COAs is not taken into account. Some test scores have been updated accordingly.
Updated the test score calculation: Peptide Partners have elected to have all their samples tested against the label claim. The "batch claim" from COAs is not taken into account. Some test scores have been updated accordingly.
Updated the test score calculation: Peptide Partners have elected to have all their samples tested against the label claim. The "batch claim" from COAs is not taken into account. Some test scores have been updated accordingly.
Batch identifier provided after publishing. Test score updated from 7.3 to 9.3.
Peptide Sciences have notified Finnrick that they do not distribute 60mg Tirzepatide. The sample submitted in this quantity, tested 17 July, was therefore removed from the site and is no longer part of the Finnrick Rating.
Batch identifier for Peptide Sciences Retatrutide 6mg vial tested 30 June was missing. Test score changed from 6.3 to 8.3.
Peptide-S Mazdutide results are being reviewed, will be updated soon.
Peptide-S Survodutide results are being reviewed, will be updated soon.
Peptidology ratings for GHK-Cu were updated from B to A, after taking into account the Batch IDs that are included on vials, but were initially not identified by Finnrick.
Peptidology ratings for BPC-157 were updated from E to C, after taking into account the Batch IDs that are included on vials, but were initially not identified by Finnrick.
Following a review request, Lab A updated their analysis to exclude the second peak from the purity calculation: it is now identified as a histidine buffer. Purity was changed from 79.802% to 99.294%.
Following a review request, Lab A updated their analysis to exclude the second peak from the purity calculation: it is now identified as a histidine buffer. Purity was changed from 80.151% to 99.395%.
Qing Li Peptides print a manufacturing date on their kit boxes. We consider this an equivalent to a batch ID, as it is clearly printed on the packaging and available for the public. When samples are submitted by the public, this identifier was not always collected, affecting test scores. This data may be collected in the future, resulting in an updated test score, and Finnrick Rating.
Lab E tests published 10 Jul 2025: change in testing and analysis methodology on 15 GHK-Cu tests previously published in May and June. New COAs were issued by the lab, and test scores have been updated.
Lab C test 5 May 2025: updated quantity rating, clerical error, value was missing.
Lab A test 27 Feb 2025, lab C test 28 Feb 2025, lab B test 30 Mar 2025: updated batch claim quantity, label claim was clear, erroneously listed 10mg.
Lab B test 19 Feb 2025: updated quantity following the identification of a clerical error, value was erroneously listed as 9.27mg. Lab issued an updated test certificate on 7 Apr 2025.
Lab B test 19 Feb 2025: updated quantity following the identification of a clerical error, value was erroneously listed as 6.25mg. Lab issued an updated test certificate on 7 Apr 2025.
Lab A test 5 Mar 2025: updated compound identification, removed purity/quantity. Error in data transcription by Finnrick: compound was incorrectly reported as BPC-157.
Lab A test 28 Feb 2025: updated compound identification, removed purity/quantity. Error in data transcription by Finnrick: compound was incorrectly reported as CJC-1295.
Lab A test 14 Feb 2025: updated compound identification, removed purity and quantity values. Error in analysis by Lab, compound was incorrectly identified as Retatrutide. Lab issued an updated test certificate.
Lab A test 14 Feb 2025: updated compound identification, removed purity and quantity values. Error in analysis by lab, compound was incorrectly identified as Retatrutide. Lab issued an updated test certificate.
Lab A tests 20 Mar 2025: udpated quantity. Error in analysis by lab, quantity was incorrectly reported as 7.009mg, 6.887mg, 6.942mg. Lab issued an updated test certificate.
Lab A test 27 Feb 2025: updated quantity. Error in analysis by lab, quantity was incorrectly reported as 9.868mg. Lab issued an updated test certificate.
Lab A test 19 Feb 2025: updated compound identification, removed purity/quantity. Error in data transcription by Finnrick: compound was incorrectly reported as CJC-1295.
Lab C tests 10 Mar 2025: error for Batch Qty on test result SPL-0511-S01, corrected with new result from Lab